Project Grant R44NS141534
Award Date
5/20/25
Completion Date
4/30/28
Dollars Obligated
$862K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $391,903 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports the development of an antisense oligonucleotide (ASO) therapeutic to upregulate the sodium channel NAV1.1 for the treatment of Dravet syndrome, a severe epileptic encephalopathy. The proposed two-phase project aims to characterize the pharmacokinetics and...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on developing bispecific antibody-antisense oligonucleotide (BAB-ASO) conjugates to selectively modulate gene expression in neurons. The $618,925 award to the Regents of the University of Michigan aims to accomplish two key objectives: Evaluate the efficacy of a...
This $337,088 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to establish a versatile platform for delivering RNA therapeutics specifically to the central nervous system (CNS). The project seeks to develop an innovative delivery system that integrates high-efficiency RNA encapsulation, precise cell targeting, and minimal cellular disruption. The key objectives are to engineer...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $504,505 to Bolden Therapeutics Inc. to conduct preclinical characterization of splice-modifying antisense oligonucleotides (ASOs) targeting neurogenesis in human Alzheimer's disease (AD) neural cells. The goal is to evaluate lead candidate exon-skipping ASOs in human neural cell culture to assess their ability to modulate the target, alter protein expression, and impact signaling and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development and validation of Artificial Axons, a novel 3D-printed drug discovery platform for identifying remyelinating compounds to treat multiple sclerosis (MS) and other myelin diseases. The $506,083 award to Artificial Axon Labs Inc., an MIT spinout, aims to achieve two key...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $563,343 Project Grant (R01NS140233) to New York University School of Medicine under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The grant supports research focused on understanding how tissues move and split to form neural cell clusters and layers during nervous system development. The researchers aim to use the zebrafish posterior lateral...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $419,038 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of North Dakota to develop a miniature selective plane illumination fluorescence microscope for high-resolution volumetric imaging in freely behaving mice. The goal is to create a transformative machine learning-augmented miniature adaptive optics light-sheet microscopy platform to...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $2,503,949.00 to Rockefeller University for a research project titled "Applying RNA Logic in Space and Time to Neurologic Disease." The project aims to develop new techniques and concepts to discover therapeutic targets for neurological diseases. Key focus areas include...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, funds research at Tufts University to develop a hybrid differentiation strategy for generating region-specific neural and oligodendrocyte cell populations from human pluripotent stem cells. The project aims to optimize protocols for rapidly differentiating region-specific...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $458,154 to Microcures Inc. to conduct proof-of-feasibility studies for a nanoparticle-encapsulated small interfering RNA (siRNA) therapy targeting the Fidgetin-like 2 (FL2) protein. This therapy aims to promote tissue repair and functional recovery after spinal cord injury...